INTRODUCTION
Despite improved prevention and treatment of cardiovascular diseases, they are still the leading cause of morbidity and mortality in Western countries. In peripheral arterial disease, occluded arteries cannot provide sufficient blood flow to the extremities resulting in tissue ischemia. New treatment strategies are needed for those patients who are not suitable for conventional revascularization methods. However, despite the efforts during the last two decades for the development of therapeutic angiogenesis, clinical trials have failed or reported only very modest effects probably either due to low gene transfer efficacy or short transgene expression insufficient for the maturation of neovessels. 1, 2 Adenovirally delivered vascular endothelial growth factor-A 165 is a very potent agent to increase skeletal muscle perfusion. 3 Previously, naked plasmid DNA and adenovirus-mediated gene transfers have been used in clinical trials for therapeutic angiogenesis without convincing efficacy on hard clinical endpoints such as amputation rate. [4] [5] [6] Thus, vectors capable of efficient long-term gene expression are probably needed for clinical success. Also, these vectors need to be tested for long-term effects in clinically relevant large animal models.
Adeno-associated virus (AAV) is a small parvovirus, which has many benefits such as nonpathogenicity, a wide range of infectivity and a long expression time. [7] [8] [9] There are studies following the transgene expression and effects in the long-term. [10] [11] [12] However, not much is known about the expression of angiogenic growth factors delivered by AAV in large animal models. Previously, the effects of AAV vascular endothelial growth factor A (AAV-VEGF-A) on angiogenesis in ischemic skeletal muscle have been primarily evaluated in small animal models for time points no longer than 6 months. It has been shown that AAV-VEGF-A induces angiogenesis in a rat hindlimb ischemia model and stimulates skeletal muscle regeneration in a mouse hind limb ischemia model. 13, 14 Here we investigated the effects of long-term VEGF-A expression in normal and ischemic rabbit hindlimb skeletal muscles. We followed muscle perfusion with a novel ultrasound method 15 on a weekly basis for up to 1 year, and discovered that perfusion in skeletal muscles remained increased for the entire follow-up time. However, we also observed dramatic changes in skeletal muscle morphology including aberrant vascular structures inside myofibers and skeletal muscle fibrosis.
RESULTS

AAV-VEGF-A increases local perfusion in skeletal muscles
Functionality of the serotype 2 AAV-VEGF-A construct was shown in vitro before in vivo gene transfers. AAV-VEGF-A-transduced HeLa cells expressed human VEGF-A in a dose-dependent manner as analyzed with western blot and enzyme-linked immunosorbent assay (ELISA) (Figure 1 ). Increase in skeletal muscle perfusion measured by contrast pulse sequence (CPS) ultrasound was confined to the same region in the semimembranosus muscle where the virus was injected (Figures 2a-d ).
Increased perfusion in normoxic muscle at the injected region 1 month after gene transfer is shown in Figure 2b . Figures 2c and d show a Doppler ultrasound image and a CPS image, respectively, in the same AAV-VEGF-A-transduced muscle 12 months after gene transfer, demonstrating a long-term effect on muscle blood flow at the same position as after injection. Doppler image shows increased blood flow in large arteries and veins whereas CPS imaging has a superior resolution, and perfusion in enlarged capillaries is also visible. 15 Notably, no visible muscle edema was detected by ultrasound imaging after AAV-VEGF-A gene transfer. No changes in perfusion were detected in AAV-LacZtransduced muscles 6 months after ischemia and gene transfer (Figures  2e and f) . In comparison, similar increase in perfusion as in AAV-VEGF-A-transduced normal muscles is seen in images of AAV-VEGF-Atransduced muscles 6 months after the ligation of the profound femoral artery and gene transfer (Figures 2g and h ). Quantitative analysis of Doppler and CPS perfusion in normal muscle (Figure 2i ) demonstrates a maximum 12-fold elevation in perfusion compared with controls and perfusion remained increased for the entire follow-up time of 12 months. The results of CPS ultrasound and native Doppler ultrasound imaging methods were very similar. Noteworthy, AAV-VEGF-A promotes a robust increase in perfusion already 1 week after the gene transfer. In ischemic muscles, perfusion dropped immediately after the ischemia operation in both groups but increased for up to sevenfold in AAV-VEGF-A animals compared with the controls during the next weeks (Figure 2j ). Perfusion was normalized also in control AAV-LacZ animals already at 1 week due to spontaneous collateral growth. In the ischemic AAV-VEGF-A group, Long-term VEGF-A expression promotes capillary enlargement and sprouting Histology of the muscles 1 and 6 months after AAV-VEGF-A gene transfer showed capillary enlargement (Figures 3a and b) . Strong angiogenesis was seen in the histology of AAV-VEGF-A-transduced muscles even a year after gene transfer (Figure 3c ). Interestingly, aberrant vascular structures inside myocytes were seen in endothelial (CD31) stainings. AAV-LacZ did not induce angiogenesis at long-term follow-up (Figures 3d and e) . Quantified mean capillary area in AAV-VEGF-A-transduced muscles was six times larger than in AAV-LacZ control group at 1 month (P¼0.03) (Figure 3f ). Six months after ischemia operation and gene transfer the mean capillary area in AAV-VEGF-A group was four times larger than in AAV-LacZ group (P¼0.05) (Figure 3f ). In addition to the enlargement of capillaries, capillary number per myocyte was significantly increased at 6 months probably due to sprouting angiogenesis (P¼0.05) (Figure 3g ). Plasma protein extravasation, quantified with the modified Miles assay, was not increased in AAV-VEGF-A-transduced muscles compared with AAV-LacZ controls 1 month after gene transfer. Six months after gene transfer increase in edema was detected (P¼0.05) (Figure 3h ). When quantified with ELISA, there were no significant differences in VEGF-A amounts (pg mg À1 ), although there was a trend towards slightly increased levels of VEGF-A in AAV-VEGF-A-transduced muscles as compared with AAV-LacZ-transduced muscles (112±60 and 85±39, respectively) at 6 months. In contrast, VEGF-A levels were elevated by fivefold compared with AAV-LacZ at 1 month (data not shown). No significant changes in VEGF-A levels or differences in tissue histology between the study groups were observed in non-transduced safety tissues: heart, lungs, liver, spleen, kidney and ovaries or testis, (data not shown). No alterations in clinical chemistry or blood tests were found between AAV-VEGF-A and AAV-LacZ transduced animals (data not shown). 
Tissue morphology and transgene expression
DISCUSSION
In this study, we investigated the long-term effects of VEGF-A expression in rabbit hindlimb. Information about long-term effects of one of the strongest vascular growth factors, VEGF-A, is essential when designing clinical applications for effective cardiovascular gene therapy. AAV-VEGF-A gene transfer was done both into normoperfused and moderately ischemic muscles to investigate its effects on perfusion and tissue morphology in both conditions. We measured tissue perfusion on a weekly basis, and analyzed histology 1, 6 and 12 months after gene transfer. In gene transfer applications, it is important to cover the target area as efficiently as possible without the dissemination of the virus in unwanted organs. In contrast to the more widely spreading adenovirus, AAV binds heparan sulfates on the cell membrane, 16 which limits its diffusion in tissues. We found that AAV-VEGF-A is expressed exactly in the same area where the virus was injected as seen in highresolution ultrasound images. In addition, VEGF-A itself binds to heparin on the cell surface, 17 which causes local protein expression next to the transduced cells. This difference between adenovirus and AAV should be kept in mind when analyzing the effects and efficacy of AAV. It could be that more injections are needed with AAV than with adenovirus to reach the target area properly, which may cause unnecessary muscle damage. On the other hand AAV may not escape from the transduced muscle increasing safety. 
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AAV-VEGF-A is known to induce angiogenesis in different models. 13, 18 Here skeletal muscle perfusion in rabbit hindlimb was increased up to 12-fold compared with controls 1 month after the gene transfer. When perfusion was measured at longer time points we observed that enhanced perfusion remained B10-fold increased even 1 year after AAV-VEGF-A gene transfer. This is the longest follow-up so far after AAV-VEGF-A-mediated gene transfer. It was shown previously that AAV-VEGF-A was not able to enhance blood flow in rat hindlimb muscles under resting conditions. 19 However, our data show that AAV-VEGF-A strongly increases blood flow in normal muscle of a larger animal also at rest. In ischemic muscle, perfusion was sevenfold higher in AAV-VEGF-A animals than in AAV-LacZ animals 1 month after the operation and gene transfer. Lower perfusion in the ischemic muscles compared with normoxic tissue could be because of lower transduction efficiency in hypoxic tissues or due to an acute inflammatory reaction caused by ischemia. Also, the ligation of the largest conduit artery naturally restricts blood flow increase in the thigh area.
In this study, we found that long-term AAV-mediated VEGF-A expression enlarges capillaries and enhances vessel sprouting at a long time point. Increase in capillaries per myocytes might be mainly due to vessel sprouts but lower number of muscle fibers in AAV-VEGF-A animals may also contribute to these findings. Previous studies done in rodents have shown increases in capillary number. 13, 20 Also, we detected small arterioles covered with aSMA positive cell layer besides capillaries indicating maturation and arterialization of new vessels as also reported previously in mouse models. 20 Tissue edema could not be visualized in AAV-VEGF-A-transduced muscles in ultrasound imaging, indicating that AAV-VEGF-A gene transfer may not cause clinically harmful increase in tissue edema. However, AAV-mediated expression of VEGF-A increased tissue permeability quantified with Modified Miles assay significantly at 6 months after gene transfer compared with AAV-LacZ. In addition, we also detected round shaped myofibers caused by increase of free liquid in the interstitium. Increased vascular permeability by AAV-VEGF-A has also been seen before in a mouse model. 21 Histological analyses revealed that long-term AAV-VEGF-A gene transfer caused substantial morphological changes in skeletal muscles including formation of enriched extracellular matrix, hypertrophy and atrophy of myocytes, infiltration of mononuclear cells and formation of vascular structures inside muscle fibers. Enhanced extracellular matrix is proangiogenic, but fibrosis may affect flexibility and contractility of skeletal muscles. VEGF-A has been shown to recruit mononuclear cells in many studies via VEGFR-1 and neuropilin-1 stimulation [22] [23] [24] and can prolong angiogenesis via paracrine mechanims. We also observed that long-term VEGF-A expression recruits macrophages, which can promote endogenous expression of VEGF-A and lead to further enhanced angiogenesis. A few VEGF-A positive cells were seen in the transduced muscles 1 year after the gene transfer but local, even low, expression of VEGF-A is probably enough to maintain angiogenesis for long periods of time. Previously, it has been shown that newly formed vessels are stabilized after a few weeks of VEGF-A expression and tissue perfusion is permanently elevated after VEGF-A withdrawal. 23, 25 Notable histological feature was found in AAV-VEGF-A muscles: many muscle fibers in the transduced area had vascular structures inside the muscle fibers. One month after AAV-VEGF-A gene transfer these structures had red blood cells inside them but no CD31 positive endothelial layers. One year after the gene transfer the situation had changed and lumens had a CD31 positive layer, but only rare red blood cells. This might indicate that after 1 month these structures were not efficiently flushed during perfusion fixation and were not properly connected to circulation, whereas 1 year after the gene transfer red blood cells were not present after perfusion fixation suggesting efficient perfusion and connection to the circulation. A possible explanation for these vascular lacunae could be that the AAV-VEGF-A-transduced myocytes had been recognized and destroyed by the immune system and their remnants had been vascularized. This explanation is supported with findings in AAV-LacZ-transduced muscles where LacZ positive myocytes were invaded by inflammatory cells at 1 month time point. LacZ gene does not have a particular effect on the skeletal muscle, which may explain why histology at 6 months time point has normalized in AAV-LacZ-transduced muscles while vascular structures were formed in AAV-VEGF-A-transduced muscles. AAV has a high natural tropism to skeletal muscle, 9 which may cause too efficient transgene expression in muscle cells leading to a strong immune reaction and abnormal tissue structures. Similar vascular structures have been reported at shorter time points. 19, 26 However, further studies are clearly needed to clarify this phenomenon.
Apart from the findings at the local site of gene transfer, general safety of the intramuscular AAV-VEGF-A gene transfer in rabbit hindlimbs seems acceptable. Neither increased levels of human VEGF-A were found in ectopic organs nor were there any histological differences outside of the target muscles present in AAV-VEGF-A animals compared with AAV-LacZ animals. In addition, intramuscular AAV-VEGF-A gene transfer did not affect blood values. These observations are important for the safety of VEGF-A gene therapy because systemic long-term expression of VEGF-A has been reported to induce tumor formation and bleeding in tissues. 27 In summary, AAV-VEGF-A is a powerful angiogenic vector and it can promote long-lasting angiogenesis also in the hindlimb model of a large animal. Importantly, long-lasting expression of VEGF-A appears to lead to local unfavorable effects, which should be considered when designing further therapeutic applications with this vector. Our results suggest that AAV-VEGF-A as a therapeutic vector in clinical applications needs a mechanism for the regulation of transgene expression. Positive results in a mouse model have been observed with an inducible vector. 21 Inducible vectors may be used but they may be less strong and therefore possibly not efficient enough in larger animals or in clinical use compared with constitutively expressing vectors. This study shows that AAV-VEGF-A has significant potential for therapeutic use. However, one needs to investigate ways to improve the vector design to achieve optimal therapeutic effects without possible harmful side effects, which may prevent the clinical use of currently available AAV vectors.
MATERIALS AND METHODS
Virus preparation and testing
Serotype 2 AAV-VEGF-A virus was produced in our laboratory based on AAVHelper-Free System method (Stratagene, La Jolla, CA, USA). Human VEGF-A 165 cDNA was subcloned to pAAV-MCS and viruses were produced in 293T cells. Virus was isolated with iodixanol gradient centrifugation and purification of the virus was done with heparin affinity chromatography. Transgene expression was tested with virus transductions in 293T cells with different multiplicity of infections (200-20 000). VEGF-A levels and dose response were measured from media collected 72 h after transduction with western blot and ELISA. Western blot was done as described. 28 In electrophoresis 10 mg of the total protein was separated in SDS-polyacrylamide gel electrophoresis gel and proteins were blotted into a nitrocellulose membrane. Monoclonal anti-human VEGF-A antibody (1:500, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was used as a primary antibody. Proteins were visualized using horseradish peroxidase-conjugated secondary antibody and ECL Plus detection system (GE Healthcare, Little Chalfont, UK), and detected with Typhoon Long-term VEGF-A expression in skeletal muscle H Karvinen et al
Gene transfer
New Zealand White rabbits (female and male; 2.5-3 kg) were used for in vivo gene transfer experiments. Intramuscular gene transfer was done in the hindlimb semimembranosus muscle as described. 3, 22 Briefly, rabbits were anesthetized with medetomidine (Domitor 0.3 mg kg À1 , Orion, Espoo, Finland) and ketamine (Ketalar 20 mg kg À1 , Pfizer, Espoo, Finland) and the total dose of 1Â10 11 virus particles in 1 ml of 0.9% NaCl was divided into 10 100 ml injections. To induce local ischemia in the target semimembranosus muscle, ligation of the profound femoral artery was performed as described 3 and gene transfer in ischemic muscles was done on the same day as the ischemia operation. Animals treated with gene transfer into normoperfused muscles were euthanized 1 month and 12 months after the gene transfer, and animals with ischemia operation and gene transfer were euthanized at 6 months. After euthanasia, animals were perfusion-fixed with 1% paraformaldehyde in 0.05 M citrate buffer, pH 3.5, via the left ventricle. Samples for histology, the Modified Miles assay and protein analysis were collected. All animal experiments were approved by the Finnish Experimental Animal Committee.
Ultrasound imaging
Tissue perfusion in transduced muscles and contralateral intact muscles was measured with Siemens Acuson Sequoia 512 system and high resolution Contrast Pulse Sequence (CPS, Siemens, Malvern, PA, USA) ultrasound imaging technique 15 using the 15L8 transducer as previously described. 15, 29 CPS method uses non-linear fundamental frequencies, which results in better spatial resolution and high sensitivity to contrast media, and provides improved tissue subtraction than previous ultrasound perfusion imaging techniques. 30, 31 Transversal images of semimembranosus muscles of both limbs were captured after a single bolus (0.5 ml) of SonoVue contrast microbubbles (Bracco, Milan, Italy) with the following parameters at 8.0 MHz: power À16 dB, mechanical index 0.31, CPS gain À10 and depth 20 mm. Measurements were done once a week for the first month and thereafter twice a month, and the imaged area was the same in each time. Muscle perfusion was quantified with the DataPro 2.13 software (Noesis, Courtaboeuf, France) and the perfusion ratio between transduced muscle and intact muscle was quantified using the maximal signal intensities as previously reported. 15 
Modified miles assay
Modified Miles assay was used to evaluate the leakiness of newly formed vessels. 3, 22 Evans Blue dye (30 mg kg À1 ) binding to plasma proteins was injected 30 min before euthanasia via the ear vein. Muscle samples were taken from both transduced muscles and contralateral intact muscles and weighted. Evans Blue dye was eluted in formamide and the released dye was quantified with spectrophotometer at 610 nm. Absorbances were normalized to sample weights and the ratio between transduced and intact muscle samples was calculated reflecting the permeability of neovessels.
Tissue histology and gene expression
Muscles were collected after perfusion-fixation and immersion fixed in 4% paraformaldehyde in 7.5% sucrose for 4 h. 32 Heart, lungs, liver, spleen, kidney and ovaries or testis were collected as safety tissues and processed similarly. Samples were embedded in paraffin and cut to 7 mm sections. Hematoxylineosin staining was used to characterize tissue morphology. Immunostainings were done by using mouse monoclonal antibody (mAb) CD31 (1:50, Dako, Glostrup, Denmark) for vascular endothelium, mouse mAb aSMA (1:500, Sigma, St Louis, MO, USA) for smooth muscle cells, mouse mAb RAM11 (1:500, Dako) for monocyte-macrophages and mouse mAb anti-human VEGF-A (1:250, Santa Cruz Biotechnology, Inc.) for expressed human VEGF-A165. LacZ expression was detected with mAb anti-bgalactosidase (1:250, Promega, Madison, WI, USA). Avidin-biotin-horse radish peroxidase system with diaminobenzidine (Vector Laboratories, Burlingame, CA, USA) was used for signal detection. Samples for ELISA measurements were isolated from snap frozen tissues with T-PER lysis buffer (Pierce, Rockford, IL, USA). Anti-human VEGF-A ELISA kit (R&D Systems) was used to measure VEGF-A levels and total protein amounts were measured with BCA kit (Thermo Fisher Scientific, Waltham, MA, USA).
